[Elsevier]
OA09.03 Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
This post will be closed automatically in 2026-09-25 05:05
Reward10points
Revista: Journal of Thoracic Oncology
Autores: A. Xiong; N. Yang; X. Dong; Y. Fan; L. Xu; P. Pan; Y. Yu; J. Zhou; Y. Li; J. Cui; M. Wang; Y. Zhang; R. Chen; H. Niu; H. Qin; S. Guo; D. Huang; H. Wu; W. Yao; Z. Zhang; J. Fang; Y. Fang; M. Li; L. Liu; W. Su; Z. Wu; X. Wang; H. Liu; J. Hu; X. Xiang; C. Zhou
20